Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737296 | 0.80 | CYP2A6 (0.50) | CYP2A6PRKCIALDH1A1 | |
| SCHEMBL22758448 | 0.79 | HTR2A (0.35) | HTR2AHTR2CHTR2BSIGMAR1ALDH1A1 | |
| SCHEMBL20372824 | 0.75 | CYP2A6 (0.49) | CYP2A6ALDH1A1 | |
| SCHEMBL14260571 | 0.74 | GABRA1 (0.40) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL22363299 | 0.72 | CYP2A6 (0.47) | CYP2A6 | |
| SCHEMBL22374289 | 0.72 | LOXL2 (0.52) | HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL20098721 | 0.71 | RAB9A (0.43) | CYP2A6 | |
| SCHEMBL1769790 | 0.69 | CYP2A6 (0.47) | CYP2A6HTR2AHTR2CHTR2BPRKCI | |
| SCHEMBL22063833 | 0.68 | HTR2A (0.33) | HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL25515309 | 0.68 | ALOX5 (0.34) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CYP2A6 2675/4885HTR2A 3908/4885HTR2C 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.